USPTO serial 87696005
HYLEUKIN
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- PRATER, JILL I
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with HYLEUKIN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Seongnamsi, Gyeonggido, KR
Seongnamsi, Gyeonggido, KR
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
James R Menker
JAMES R MENKER HOLLEY & MENKER, PAPO BOX 331937ATLANTIC BEACH, FL 32233UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Antibiotics; Anti-cancer preparations; Anti-inflammatory preparations, namely, anti-inflammatory gels, ointments, salves, sprays, creams, pills, powders, granules, tablets, capsules, depots, suppository, syrup, tinctures and emulsion; Antiviral agent against human papilloma virus; Blood solvent, namely, blood plasma, albumin, globulin, fibrinogen, thrombocyte and platelets; Cardiovascular pharmaceutical preparations for the treatment and prevention of heart and vascular diseases; Dermatological pharmaceutical products; DNA vaccines; Drugs for medical purposes, namely, pharmaceutical drug preparations for the treatment and prevention of human papilloma virus infectious disease, cancer and cervical intraepithelial neoplasia; Injectable pharmaceuticals for medical purposes, namely, for the treatment and prevention of human papilloma virus infectious disease, cancer and cervical intraepithelial neoplasia; Medicines for sensory organs, namely, pharmaceutical preparations for the prevention, treatment, and cure of diseases and conditions impacting the eyes, ears, nose, mouth and nervous system; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical preparations and compositions for the treatment and prevention of cancer; Pharmaceutical preparations for activating cellular function; Pharmaceutical preparations for anticancer immunotherapy; Pharmaceutical preparations for digestive organs, namely, for the prevention, treatment, and cure of diseases and conditions impacting digestive organs; Pharmaceutical preparations for gene therapy; Pharmaceutical preparations for immunomodulatory purposes, namely, for the regulation of immune functions; Pharmaceutical preparations for immunotherapy; Pharmaceutical preparations for preventing and treating obese; Pharmaceutical preparations for regulating the immune system; Pharmaceutical preparations for the prevention of osteoporosis; Pharmaceutical preparations for the treatment of autoimmune diseases; Pharmaceutical preparations for the treatment of cardiovascular disease; Pharmaceutical preparations for the treatment of cervical cancer; Pharmaceutical preparations for the treatment of cervical intraepithelial neoplasia; Pharmaceutical preparations for the treatment of cervical pre-cancer; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of head and neck cancer; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical preparations for the treatment of multiple sclerosis; Pharmaceutical preparations for the treatment of osteoporosis; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating malignant tumours; Pharmaceutical preparations for urogenital organs; Pharmaceutical preparations for wounds; Pharmaceutical products and preparations, namely, for the treatment and prevention of human papilloma virus infectious disease, cancer and cervical intraepithelial neoplasia; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of cancer; Pharmaceutical products for the treatment of infectious diseases; Pharmaceutical products for the treatment of viral and infectious diseases; Pharmaceutical products for the treatment of viral diseases; Preventive vaccines; Preventive vaccines against human papilloma virus infections; Therapeutic vaccines; and Vaccines | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 13, 2020 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jul 13, 2020 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Dec 4, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 2, 2019 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Dec 2, 2019 | EXT3 | SOU EXTENSION 3 FILED | — |
| Dec 2, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 8, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 6, 2019 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Jun 6, 2019 | EXT2 | SOU EXTENSION 2 FILED | — |
| Jun 6, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 13, 2018 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 11, 2018 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Dec 11, 2018 | EXT1 | SOU EXTENSION 1 FILED | — |
| Dec 11, 2018 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 12, 2018 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Apr 17, 2018 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 17, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 28, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 9, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 8, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 5, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 27, 2017 | NWAP | NEW APPLICATION ENTERED | — |